drugset / Trial / NCT03987685
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, nonrandomized, open-label, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing of Oratopo. No control group has been included.
Timeline
- Start
- 2018-07-19
- Primary completion
- 2021-01-09
- Completion
- 2021-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM30181AK | Unknown | — | Oral |
| Subject | Topotecan | Small molecule | — | Oral |